Skip to main content
GH
NASDAQ Life Sciences

Q3 Revenue Jumps 36% to $361M, 2026 Guidance Raised on Shield Momentum

Tom Rudovsky · Reported by BusinessWire
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$159.34
Mkt Cap
$20.59B
52W Low
$74.55
52W High
$191.05
52W Position info
114% above low
Off High info
17% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

GH has more than doubled off its 52-week low of $74.55 on elevated volume (2.0× avg).

Summary

Guardant beat its own trajectory with Q3 revenue of $361.0 million, up 36% year over year, and lifted full-year 2026 revenue guidance to $1.36-$1.37 billion from $1.34-$1.36 billion. Screening is the engine: Shield revenue hit $67.6 million, up 180%, on 83,000 tests versus 24,000 a year ago, and management raised the screening outlook to $233-$238 million from $218-$230 million. Oncology grew 25% to $231.3 million with test volume up 58%. The offset is spending — non-GAAP operating expenses guidance rose to $1.105-$1.125 billion and free cash flow burn guidance widened to $205-$220 million from $195-$205 million, even as the non-GAAP net loss per share narrowed to $0.29 from $0.39 and the GAAP loss per share came in at 93 cents. This follows the November 3rd 8-K granting co-CEOs performance stock units tied to relative total shareholder return, aligning management pay with the stock. The quarter also carried regulatory wins: FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH and for INLURIYO plus VERZENIO, plus a PMA submission for Guardant360 Tissue. Watch whether the higher opex and cash burn get questioned on the 4:30 pm ET call against the raised revenue line.

At the time of this announcement, GH was trading at $159.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.6B. The 52-week trading range was $74.55 to $191.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

GH - Latest Insights

GH
Nov 16, 2026, 4:19 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.80
Real-time Price: $137.31 info
Change: -$5.49 (-4%) info
Market Cap: $19.696B info
GH
Nov 12, 2026, 1:09 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $155.00
Real-time Price: $137.31 info
Change: -$17.69 (-11%) info
Market Cap: $19.696B info
GH
Nov 11, 2026, 4:17 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $154.78
Real-time Price: $137.31 info
Change: -$17.47 (-11%) info
Market Cap: $19.696B info
GH
Nov 05, 2026, 5:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $130.02
Real-time Price: $137.31 info
Change: +$7.29 (+6%) info
Market Cap: $19.696B info
GH
Oct 08, 2026, 4:12 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $165.56
Real-time Price: $137.31 info
Change: -$28.25 (-17%) info
Market Cap: $19.696B info